Gulf Capital unveils growth plans following $100mln IVI-RMA Mideast acquisition

The expansion plan will initiate a new platform-wide brand identity in 2020, include the inauguration of a cutting-edge genetics lab in Abu Dhabi, and also increase the number of clinics by more than three-fold to total nine taking the provider to new markets in the Middle East, Asia, and Europe, according to a press release.

Gulf Capital, who is vigorously targeting investments within the fast-growing and defensive healthcare sector, has seen the fertility sub-sector as a key priority, thanks to its expected double-digit growth rates regionwide. The fertility segment is likely to grow at 15%+ Compound annual growth rate (CAGR) annually over the next five years.

Launched in early 2016, IVI-RMA Middle East has proven itself in the UAE and Oman, increasing at a 50% CAGR since inception due to very high success rates relative to industry peers.

Commenting on this major, CEO of Gulf Capital, Karim El Solh, said, “The investment in IVI-RMA Middle East is Gulf Capital’s largest equity investment to date and is the first corporate carve-out in our Firm’s history.”

Meanwhile, the managing director at Gulf Capital, Hazem Abu Khalaf, concluded, “With a regional market expected to continue to expand at a double-digit growth rates over the next five years, we are confident that our partnership will enable the team to expand its coverage and services into new territories globally and to deliver market-leading success and live birth rates.”